Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
56 participants
OBSERVATIONAL
2012-07-31
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pain Assessment, Incidence & Nature in Heart Failure
NCT00444301
Preliminary Study Examining Heart Failure Patients Responses to Depression Education
NCT01794598
Improving Care of Patients With Heart Failure
NCT01461681
Evaluation of a Primary Care Based Heart Failure Management Program
NCT00182182
Cost and Shared Decision-Making for Heart Failure
NCT04793880
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects will sign an informed consent to participate in HELP-HF. A selection of assessment questionnaires (listed below) and performance measures will be completed during the index hospitalization and at a subsequent follow up clinic visits or by telephone call. Some of these assessments involve data collection from standard of care encounters or tests and will be abstracted from the medical record.
The Kansas City Cardiomyopathy Questionnaire (KCCQ) The KCCQ is a valid, reliable and responsive health status measure for HF patients and serves as a clinically meaningful outcome assessment tool that is widely used in cardiovascular research, patient management, and quality of life self-assessment.12 The Brief Pain Inventory (BPI) The BPI is one of the most widely used measurement tools for assessing clinical pain. It allows patients to rate the severity of their pain and the degree to which their pain interferes with common dimensions of feeling and function. Initially developed to assess pain related to cancer, the BPI has validated as an appropriate measure for pain caused by a wide range of clinical conditions. , The Charlson Co-Morbidity Index (CCI) Comorbidity describes the effect of all other diseases an individual patient might have other than the primary disease of interest. The CCI is used to characterize comorbid medical conditions and allows inferences about the extent to which symptoms and other factors related to quality of life may be attributable to conditions other than HF. The CCI designates comorbid conditions in 19 categories and each category has an associated weight based on the adjusted risk of one-year mortality, and the overall comorbidity score reflects the cumulative increased likelihood of one-year mortality. Charlson scores can range between 0 and 35, with a higher score indicating increase in burden of comorbid disease.
OTC Medication Inventory A comprehensive list of any over the counter (OTC) medications will be collected and reconciled via review of the electronic medical records and by subject interview.
Brief Interventions Measures (BIM) The BIM questionnaire is a novel tool developed for use in the HELP-HF study. It is adapted from similar questionnaires used in palliative oncology care and incorporates an inventory of comfort measure identified in the literature. These include measures like application of heat or cold, massage, and other self-selected therapies.
Case Report Form and Data Capture A paper case report form (data collection tool) will be developed for each subject's study records. All data will be entered by study personnel into a password-protected database using the REDCap (Research Electronic Data Capture) system. REDCap is a secure, web-based application designed to support electronic data capture for research studies. REDCap is used by selected areas within the University. It is a service available via a free collaboration with the NIH CTSA structure and accessed at TJU with permission and oversight via internal Information Systems at the University's Kimmel Cancer Center. REDCap allows for monitored dual data entry via a web-based system that is maintained on a protected server and will be used by the study investigators, coordinators and statistician.
Statistical Analyses Plan Subject demographics and co-morbidities as well as characteristics of the self-reported pain, treatment selections, and efficacy will be reported as medians and interquartile ranges (IQRs) for continuous variables and as percentages of non-missing values for categorical variables. Patients will be stratified by pain scores. Univariate comparisons between patients with and without pain will be performed using the Pearson χ2 test for categorical variables and the Wilcoxon rank-sum test for continuous and ordinal variables.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Elderly inpatients with heart failure
A single cohort group of elderly patients hospitalized for heart failure.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admission to hospital for worsening HF
Exclusion Criteria
* Severe valve disease.
* End-stage (Stage D) HF, including treatment with chronic ionotropic drugs or left ventricular assist device support.
* Advanced malignancy or other medical condition with life expectancy less than 2 years or undergoing active chemotherapy or radiation therapy.
* Advanced chronic kidney disease (CKD) defined as estimated glomerular filtration rate (GFR) \< 20 mL/min/1.73 m2 based upon the Modification of Diet in Renal Disease (MDRD) study equation), or on chronic or intermittent dialysis or dialysis anticipated within the next 6 months.
* Chronic anemia with hemoglobin \< 9 gm/dl for males, \< 8 gm/dl for females or acute anemia requiring transfusion of 2 or more units of blood.
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
INDUSTRY
Thomas Jefferson University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David J Whellan, MD MHS
Role: PRINCIPAL_INVESTIGATOR
Thomas Jefferson University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12D.115
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.